TransMedics Group (TMDX) Tops Q2 EPS by 14c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
TransMedics Group (TMDX) PT Raised to $200 at Oppenheimer
August 1, 2024 6:04 AM EDTOppenheimer analyst Suraj Kalia raised the price target on TransMedics Group (NASDAQ: TMDX) to $200.00 (from $125.00) while maintaining a Outperform rating.
The analyst comments "TransMedics reported 2Q24 revs. of $114.3M, blowing past our/consensus $100.2M/$98.8M estimates. In Q2, ~126 (+21 seq.; ~55 liver, ~57 heart, ~14 lung) transplant... More
